Clinical Trials Browser

TAK-243 × Clear all

NCT03816319 2026-03-17

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Phase 1 Recruiting

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06223542 2025-09-29

Studying TAK-243 in Patients With Advanced Cancer

Phase 1 Recruiting

Neoplasm Metastasis

NCT02045095 2019-03-14

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Phase 1 Terminated

29 enrolled 25 charts

Other solid neoplasm

Advanced Malignant Solid Tumors